Wave Life Sciences Financials - Benzinga

Wave Life Sciences Inc

WVENASDAQ

Trade with Public

Trade with Public

$4.25

-0.0987-2.27%

Ult. Agg.: Sep 23, 9:29 AM

PRO

Perché si muove?:Wave Life Sciences shares are trading lower after JP Morgan downgraded the ...

Panoramica Notizie Previsioni utili Eventi Obiettivi di prezzoDati finanziariSentiment Azionariato Confronta Opzioni Rapporto azionario

Wave Life Sciences Financials

Wave Life Sciences (WVE) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
WAVE Life Sciences Q2 EPS $(0.34) Misses $(0.31) Estimate, Sales $2.272M Miss $7.050M Estimate

WAVE Life Sciences (NASDAQ:WVE) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.31) by 9.68 percent. This is a 9.68 percent decrease over losses of $(0.31) per share

Benzinga Newsdesk

PRO
Wave Life Sciences Reports Cash And Cash Equivalents Of $544.6M As Of March 31, 2026, With Expected Cash Runway into Q3 2028

Benzinga Newsdesk

PRO
WAVE Life Sciences Q1 EPS $(0.13) Beats $(0.33) Estimate, Sales $38.246M May Not Be Comparable To $9.119M Estimate

Benzinga Newsdesk

Earnings Scheduled For April 28, 2026

Benzinga Insights

Earnings Summary: WAVE Life Sciences Q4

Benzinga Insights

PRO
WAVE Life Sciences Reported Cash And Cash Equivalents Of $602.1M As Of December 31, 2025 And Expected Cash Runway Into Q3 2028

Benzinga Newsdesk

© 2026 Benzinga | All Rights Reserved